Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year Low – Here’s Why

Vera Therapeutics, Inc. (NASDAQ:VERA – Get Free Report)’s share price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $26.23 and last traded at $26.7450, with a volume of 1,213 shares traded. The stock had previously closed at $26.97.

Analysts Set New Price Targets

VERA has been the topic of several recent analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Vera Therapeutics in a research note on Friday, October 23rd. HC Wainwright dropped their price objective on shares of Vera Therapeutics from $90.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, November 6th. Leerink Partners began coverage on Vera Therapeutics in a research note on Monday, October 12th. They issued a “market perform” rating and a $34.00 target price on the stock. Wall Street Zen upgraded shares of Vera Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Finally, TD Cowen reissued a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $74.93.

Read Our Latest Report on Vera Therapeutics

Vera Therapeutics Stock Down 1.9%

The firm has a fifty day moving average of $30.93 and a 200-day moving average of $36.15. The company has a quick ratio of 10.92, a current ratio of 7.91 and a debt-to-equity ratio of 0.23. The firm has a market cap of $1.91 billion, a P/E ratio of -4.49 and a beta of 1.07.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.32. The company had revenue of $10.28 million during the quarter, compared to the consensus estimate of $3.42 million. On average, equities research analysts anticipate that Vera Therapeutics, Inc. will post -6.00 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total value of $684,500.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares of the company’s stock, valued at approximately $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP lifted its stake in Vera Therapeutics by 66.3% in the third quarter. Allworth Financial LP now owns 1,515 shares of the company’s stock valued at $49,000 after acquiring an additional 604 shares during the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in shares of Vera Therapeutics in the 3rd quarter valued at about $32,000. Steward Partners Investment Advisory LLC lifted its stake in Vera Therapeutics by 110.4% in the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,045 shares of the company’s stock valued at $66,000 after purchasing an additional 1,073 shares during the last quarter. Arizona State Retirement System lifted its stake in Vera Therapeutics by 12.3% in the 2nd quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock valued at $507,000 after purchasing an additional 1,295 shares during the last quarter. Finally, ADAR1 Capital Management LLC lifted its stake in Vera Therapeutics by 8.8% in the 1st quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock valued at $645,000 after purchasing an additional 1,300 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

About Vera Therapeutics

(Get Free Report)

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated diseases. Headquartered in Brisbane, California, the company focuses on therapies intended to address underlying immune processes involved in conditions with significant unmet medical needs. Its lead investigational candidate, atacicept, is a fusion protein designed to inhibit BAFF and APRIL, proteins that support B-cell activity and antibody production. Vera is studying atacicept for IgA nephropathy and other autoimmune diseases.

Read More

Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.